从2018年到2019年评估海地结核病治疗结果:一个竞争性的风险分析
Nernst-Atwood Raphael1,2, Pierre Anthony Garraud2, Maroussia Roelens1
1Institute of Global Health, University of Geneva, Geneva, Switzerland.
IJID regions
|April 5, 2024
概括
海地结核病 (TB) 治疗成功受到年龄,性别和艾滋病毒共感染的影响. 年龄较大,男性性别和艾滋病毒共感染与较低的结核病治疗成功率有关.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 结核病 (TB) 仍然是一个重大的全球卫生挑战,需要对有效的治疗策略和预测结果进行持续的研究.
- 海地面临着相当大的结核病负担,使得本地研究对于理解和改善患者的治疗结果至关重要.
研究的目的:
- 评估海地对药物敏感结核病 (TB) 的治疗结果.
- 确定与海地人口成功治疗结核病相关的人口和临床因素.
主要方法:
- 分析了2018年至2019年期间海地药物敏感结核病患者的数据.
- 利用了Fine & Gray竞争风险模型,并进行了多次归算,以考虑潜在的偏见.
主要成果:
- 总共分析了16545名患者,总治疗成功率为66.2%.
- 在14.7%的患者中,同时存在HIV共感染.
- 年龄较大 (45岁和60岁) 和男性性别与成功治疗结果的风险降低有关.
- 与HIV阴性个体相比,同时感染艾滋病毒显著降低了成功治疗结核病的风险35.3%.
结论:
- 综合保健方法对于改善结核病治疗结果至关重要.
- 创新解决方案,包括机器学习和地理信息系统,可以帮助识别结核病热点和高负担人口,以进行有针对性的干预.
更多相关视频
相关概念视频
Pulmonary Tuberculosis V
179
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
179
Comparing the Survival Analysis of Two or More Groups
181
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
181
Pulmonary Tuberculosis I
242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Pulmonary Tuberculosis IV
142
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
142
Hazard Ratio
118
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
118


